Moderna has six Phase III programmes underway, including one for a CMV vaccine, which has completed enrolment. Credit: Tada Images via www.shutterstock.com.

Moderna has posted a reported net loss of $3.6bn in its Q3 earnings compared to a net income of $1bn during the same period last year, in line with the decreasing Covid-19-related revenues seen across the sector this year. 

For the quarter ended 1 October 2023, the company reported a diluted loss per share of $9.53. Revenues also saw a decline of 32% to $3.4bn from $5bn in the same quarter of the previous year. In its earnings release, Moderna attributed the drop in revenues to the expected decline in global revenue generated by the Covid-19 vaccine Spikevax. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Spikevax revenues saw a 42% drop against the same quarter in 2022, from $3.1bn to $1.8bn. 

Still, the US market share to date of Spikevax grew to 45% from 36% in 2022, and Moderna anticipates 2024 revenues of approximately $4bn and return to growth in 2025. Part of this sales projection is attributed to Spikevax’s global sales and the potential launch of the company’s RSV vaccine, which is currently under regulatory review.  Additionally, Moderna has six Phase III programmes underway, including one for a CMV vaccine, which has completed enrolment.  

Moderna chief executive officer Stephane Bancel said: “In the third quarter, we significantly resized our manufacturing infrastructure to make our Covid-19 franchise profitable for 2024 and beyond. We are preparing to launch multiple products through 2025, including our RSV vaccine.  

“We expect to return to sales growth in 2025 and, through disciplined investment, to break even in 2026.” 

In August 2023, the company announced a reported total revenue of $344m for Q2 2023, indicating a 92.7% decline from $4.7bn in the same quarter of 2022.